Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, underpri
Target Price
The average target price of GMAB.CO is 2382 and suggests 37% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell